AIM ImmunoTech Inc. Common Stock AIM 深 滬
等待開盤 12-12 09:30:00 美东时间
1.45
0.000
0.00%
華盛通- 最 高1.52
- 今 開1.52
- 成交量 2.63万股
- 最 低 1.45
- 昨 收 1.45
- 總市值 392.76万
- 52周最高 20.35
- 市盈率 靜 --
- 換手率 0.97%
- 52周最低 1.26
- 委 比 -2.48%
- 總股本 270.87万
- 歷史最高 20.35
- 量 比 0.31
- 振 幅 4.83%
- 歷史最低 1.26
- 每 手 1
- 風險率 2.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Inc. has published a new CEO Corner segment on its website, where Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company’s lead program, Ampligen® (rintatolimod), which is currently being evaluated in the DURIPANC Phase 1b/2 clinical trial in combination with AstraZeneca’s Imfinzi® (durvalumab). For more details, visit the company’s website.
12-10 14:00
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $22
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $24 to $22.
12-08 18:33
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
AIM ImmunoTech的CEO Thomas K. Equels将在12月4日参与Virtual Investor Closing Bell Series活动，重点讨论Ampligen的临床和监管策略，包括与AstraZeneca合作的DURIPANC试验及与Merck合作的卵巢癌试验。投资者可通过aim@jtcir.com提交问题，活动将在aimimmuno.com进行直播。
12-01 13:55
AIM ImmunoTech Q3 EPS $(1.57) Misses $(0.98) Estimate, Sales $26.000K Down From $35.000K YoY
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(1.57) per share which missed the analyst consensus estimate of $(0.98) by 59.39 percent. This is a 73.83 percent increase over losses of $(6.00) per share from the
11-18 21:57
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
AIM ImmunoTech Inc. reportedProgress in Cancer Therapy and Positive Financial Developments for Q3 2025
11-18 13:55
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced positive results from a Phase 2 clinical trial combining Ampligen with cisplatin and pembrolizumab for recurrent platinum-sensitive ovarian cancer. The study achieved a 50% overall response rate, significantly higher than previous pembrolizumab-only trials. Ampligen's ability to enhance immune response could benefit patients resistant to checkpoint inhibitors. The company holds several patents supporting this combina...
11-10 13:55
【AI纪要】谷歌、微软、Meta三巨头2025年三季度业绩深度对比分析
（来源：Gangtise投研） 一、导言 三巨头均以AI为核心驱动力，但路径分化明显——Meta押注硬件入口，谷歌强化搜索生态，微软重构企...
10-30 09:33
AIM ImmunoTech Updates Certificate of Incorporation
AIM ImmunoTech ( ($AIM) ) has issued an announcement. AIM ImmunoTech has filed ...
10-30 05:51
